{"nctId":"NCT01629563","briefTitle":"PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata","startDateStruct":{"date":"2012-06"},"conditions":["Uterine Fibroids"],"count":451,"armGroups":[{"label":"Ulipristal acetate (PGL4001) 5mg","type":"EXPERIMENTAL","interventionNames":["Drug: PGL4001 5 mg"]},{"label":"Ulipristal acetate (PGL4001) 10mg","type":"EXPERIMENTAL","interventionNames":["Drug: PGL4001 10 mg"]}],"interventions":[{"name":"PGL4001 5 mg","otherNames":["Ulipristal Acetate, Esmya"]},{"name":"PGL4001 10 mg","otherNames":["Ulipristal Acetate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be a pre-menopausal woman between 18 and 50 years inclusive.\n* Have a Body Mass Index (BMI) ≥ 18 and ≤ 40.\n* Have FSH levels ≤ 20 mIU/mL\n* Have excessive uterine bleeding due to myoma.\n* Have regular menstrual cycles\n* Have a myomatous uterus \\< 16 weeks with at least one myoma ≥ 3 cm in diameter.\n* If of childbearing potential the subject must be practicing a non-hormonal method of contraception.\n\nExclusion Criteria:\n\n* Has a history of or current uterine, cervical, ovarian or breast cancer.\n* Has a history of or current endometrium atypical hyperplasia or adenocarcinoma.\n* Has a known severe coagulation disorder.\n* Has a history of or current treatment for myoma with a Selective Progesterone Receptor Modulator (SPRM).\n* Has abnormal hepatic function at study entry.\n* Has a positive pregnancy test, is nursing or planning a pregnancy during the course of the study.\n* Has a current (within twelve months) problem with alcohol or drug abuse.\n* Is currently enrolled in an investigational drug or device study or has participated in such a study within the last 30 days.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who Are in Amenorrhea at the End of All Four Treatment Courses","description":"Amenorrhoea was defined as no more than 1 day of spotting within a 35 day interval. Subjects need to be in amenorrhoea at the end of all four treatment courses, i.e for at least 4x35 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":null},{"groupId":"OG001","value":"60.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Were in Amenorrhea at the End of Treatment Course 4","description":"Amenorrhoea was defined as no more than 1 day of spotting within a 35 day interval.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"74.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Controlled Bleeding at the End of All 4 Treatment Courses","description":"Controlled bleeding was defined as no episodes of heavy bleeding and a maximum of 8 days of bleeding during the last 56 days of a treatment course.\n\nSubjects need to be in controlled bleeding at the end of all 4 treatment courses i.e. for at least 4x56 days.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1","spread":null},{"groupId":"OG001","value":"71.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Change From Baseline to End of Treatment Course 4 in the Total Volume of the 3 Largest Fibroids","description":"For the 3 largest myomas at baseline and the 3 largest myomas at the end of treatment course 4 identified by transvaginal ultrasound, length, height and depth were measured and the volume was estimated by applying the equation for the voulme of an ellipsoid (length x height x depht x π/6).\n\nSubjects were exposed to 4 3-month intermittent courses.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-67.0","spread":null},{"groupId":"OG001","value":"-70.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Change From Baseline to End of Treatment Course 4 in Quality of Life (Uterine Fibroid Symptom Severity (UFSQoL)","description":"Quality of Life was assessed using a validated questionnaire measuring uterine fibroid symptom severity (UFSQoL) where lower scores indicate fewer symtoms and where a level of 23 has been reported for healthy subject (scale 0-100).\n\nSubjects were exposed to 4 3-month intermittent courses.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.25","spread":null},{"groupId":"OG001","value":"-28.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Change From Baseline to End of Treatment Course 4 in Quality of Life -Uterine Fibroid Health Related Quality of Life (HRQL)","description":"Quality of Life was measured using a validated uterine fibroid symptom questionnaire. Total score for health related quality of Life (HRQL) range from 0 to 100 with higher scores indicating better Quality of Life.\n\nSubjects were exposed to 4 3-month intermittent courses.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.69","spread":null},{"groupId":"OG001","value":"15.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Change From Baseline to End of Treatment Course 4 in Pain Using a Visual Analogue Scale (VAS)","description":"Pain was assessed using a Visual Analogue Scale (VAS) ranging from 0 to 100 with higher score indicating more severe pain.\n\nSubjects were exposed to 4 3-month intermittent courses.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.0","spread":null},{"groupId":"OG001","value":"-23.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":230},"commonTop":["headache","hot flush","influenza","nasopharyngitis","breast pain/breast tenderness/breast disconfort"]}}}